Auranofin (Ridaura)

An oral chrysotherapeutic agent for the treatment of rheumatoid arthritis. Its exact mechanism of action is unknown, but it is believed to act via immunological mechanisms and alteration of lysosomal enzyme activity. Its efficacy is slightly less than that of injected gold salts, but it is better tolerated, and side effects which occur are potentially less serious.

Also Known As:

Networked: 646 relevant articles (62 outcomes, 126 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Messori, Luigi: 13 articles (01/2022 - 03/2008)
2.	Seleem, Mohamed N: 11 articles (01/2022 - 03/2016)
3.	Abutaleb, Nader S: 7 articles (01/2022 - 01/2018)
4.	Arnér, Elias S J: 7 articles (01/2022 - 12/2010)
5.	Gamberi, Tania: 7 articles (01/2022 - 08/2015)
6.	Massai, Lara: 7 articles (01/2022 - 08/2015)
7.	Spitz, Douglas R: 7 articles (12/2021 - 10/2011)
8.	Liu, Jinbao: 7 articles (08/2021 - 07/2014)
9.	Debnath, Anjan: 7 articles (01/2020 - 06/2012)
10.	Reed, Sharon L: 7 articles (01/2017 - 06/2012)

Related Diseases

1.	Rheumatoid Arthritis 01/01/2019 - "Now, however, auranofin is rarely used in clinical practice despite its efficacy for treating rheumatoid arthritis because more novel antirheumatic medications are available. " 12/30/1983 - "We conclude that both drugs are effective in rheumatoid arthritis and that the lesser toxicity with auranofin will make it a valuable addition to our therapeutic armamentarium." 06/01/2010 - "Since dysregulation of TLRs can lead to severe systemic inflammatory and joint destructive process in rheumatoid arthritis, auranofin-mediated modulation of TLR activation may have therapeutic potential against such diseases. " 03/01/1984 - "Auranofin is safe and effective for short- and long-term treatment of patients with rheumatoid arthritis. " 01/01/2020 - "The aim of the present study is to investigate the in vivo efficacy of auranofin (rheumatoid arthritis FDA-approved drug) in a CDI mouse model and establish an adequate dosage for treatment. "
2.	Neoplasms (Cancer) 05/01/2014 - "In TCL-1 transgenic mice, an in vivo model of CLL, auranofin treatment markedly reduced tumor cell burden and improved mouse survival. " 01/01/2023 - "In this study, we characterized transcriptional and genetic alterations associated with auranofin response in cancer. " 01/01/2019 - "In this study, we have examined whether auranofin selectively radiosensitizes colon tumors without promoting radiation toxicity in normal intestine. " 12/01/2023 - "In vivo data showed that, compared with the clinical TrxR inhibitor auranofin (AUR), compound 1d could more effectively eliminate tumors by 90 % at a dose of 1.5 mg/kg without any obvious side effects. " 11/20/2023 - "The tested metallacages show similar IC50 values close to that of auranofin in four different cancer cell lines (MCF-7, PC-3, U383, U343), e.g. "
3.	Pain (Aches) 02/15/1988 - "The proportions of patients showing 50% or greater improvement in tender joints, swollen joints, activity index, severity of pain, general health rating, and erythrocyte sedimentation rate (ESR) were similar for both auranofin-treated and GST-treated patients who completed the 48-week trial. " 01/01/1986 - "Efficacy of auranofin was apparent by 3 months after the start of treatment, as evidenced by improvement over baseline in number of tender joints, severity of pain, and erythrocyte sedimentation rate. " 01/01/2017 - "On day 8 and at the end of the cycle, pain scores in auranofin-treated patients were more favorable, although differences were not statistically significant. " 01/01/2000 - "A statistically significant benefit was observed for auranofin when compared to placebo for tender joint scores, pain, patient and physician global assessments and ESR. " 10/01/1986 - "Auranofin was superior to placebo in the clinical (p = 0.003), functional (p = 0.001), and global (p = 0.007) composites and trended similarly in the pain composite (p = 0.021). "
4.	Juvenile Arthritis (Juvenile Idiopathic Arthritis) 01/01/1990 - "The authors describe the results of prospective multicenter Soviet-American placebo-controlled 6-month investigations concerned with assessment of the therapeutic efficacy of auranofin in juvenile rheumatoid arthritis (JRA). " 01/01/1990 - "[The evaluation of the therapeutic efficacy of auranofin in juvenile rheumatoid arthritis (the results of Soviet-American research)]." 08/01/1988 - "The safety and efficacy of auranofin in the long-term treatment of children with juvenile rheumatoid arthritis was investigated in an open study of 14 patients. " 12/30/1983 - "The results from this trial reveal sufficient patient improvement to plan a double-blind trial of auranofin in children with juvenile rheumatoid arthritis." 01/01/1983 - "The results from this trial are sufficiently encouraging to merit a double-blind trial of auranofin in children with juvenile rheumatoid arthritis."
5.	Asthma (Bronchial Asthma) 12/01/1991 - "We suggest that inhibition of bronchial hyperresponsiveness by auranofin is one of the mechanisms by which auranofin is effective against bronchial asthma." 07/01/1994 - "A recent double blind clinical trial in Japan has shown that auranofin (6 mg/day) is a useful treatment for patients with moderate to severe asthma. " 12/01/1991 - "Recently, in Japan, auranofin (6 mg/day) has been demonstrated to be a useful treatment for patients with moderate to severe asthma in a double-blind clinical trial. " 12/01/1991 - "Twenty-five adult patients with asthma received orally 3 mg of auranofin or inactive placebo twice daily for 12 weeks. " 09/01/1984 - "These results suggest that auranofin may be beneficial to patients with allergic diseases such as bronchial asthma."

Related Drugs and Biologics

1.	Gold
2.	Gold Sodium Thiomalate (Sodium Aurothiomalate)
3.	Auranofin (Ridaura)
4.	Salts
5.	Azathioprine (Imuran)
6.	Hydroxychloroquine (Plaquenil)
7.	Methotrexate (Mexate)
8.	OM 89
9.	Histamine (Histamine Dihydrochloride)
10.	Penicillamine (Cuprimine)

Related Therapies and Procedures

1.	Therapeutics
2.	Injections
3.	Immunomodulation
4.	Drug Therapy (Chemotherapy)
5.	Duration of Therapy